In 1998, I was diagnosed with metastatic melanoma and given months to live. I consulted more than a dozen leading oncologists and got conflicting recommendations. No one could tell me: ‘Which treatment is best for me?’

A clinical trial saved my life—despite itself being unsuccessful—only raising more questions. Why did this therapy work for me but not for others? Could my experience help similar patients? It was life-saving knowledge I wanted to share with all cancer patients.

Welcome to Cancer Commons.

Marty Tenenbaum, PhD Founder of Cancer Commons

Since our founding in 2011, we have delivered personalized, evidence-based guidance at no charge to more than 10,000 patients and caregivers, supported entirely by philanthropy.

  • Emma has been so helpful and kind to my wife.

    Husband of cancer patient

  • What I appreciate the most about Emma is her human goodness and empathy. I have never felt I was just a case for her.

    Marilou
    Cervical cancer survivor

  • Cancer Commons helped give me peace of mind with my treatment decision. Chief scientist Emma Shtivelman’s expert, science-based opinion made such logical sense, and it also felt right in my soul.

    Ellen
    Breast cancer patient

  • Cancer Commons is extremely engaged and proactive. Its professionals have directed us towards interesting avenues to explore in our search for additional treatment options.

    Mark
    Spouse of stage IV ovarian cancer victim

  • Cancer Commons is the absolute best for helping when diagnosed with cancer. They help you understand your cancer and all the treatment options, including clinical trials. I have relied on them for many friends, and don’t know what I would do without them.

    Reggie
    Friend of a metastatic ovarian cancer patient, and many others

Cancer Commons is staffed by accomplished researchers with PhDs in the molecular biology and pharmacology of cancer and in Artificial Intelligence. They have joined the Commons to apply their knowledge and expertise to help patients research their options in real time using the latest tools of precision oncology.